source
- Roivant's brepocitinib shows strong Phase 3 results, paving way for uveitis indicationRoivant subsidiary Priovant Therapeutics announced positive Phase 3 data for its anti‑inflammatory drug brepocitinib in patients with non‑infectious uveitis, an eye disease that can cause blindness…
- FDA and UK regulators discuss new frameworks for generative AI oversightAt the MedTech Conference in Boston, officials from the U.S. Food and Drug Administration and the U.K. Medicines and Healthcare products Regulatory Agency met to talk about how to regulate generati…